Verrica Pharmaceuticals Future Growth
Future criteria checks 5/6
Verrica Pharmaceuticals is forecast to grow earnings and revenue by 61.6% and 47.8% per annum respectively while EPS is expected to grow by 62% per annum.
Key information
61.6%
Earnings growth rate
62.0%
EPS growth rate
| Pharmaceuticals earnings growth | 22.8% |
| Revenue growth rate | 47.8% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 24 Apr 2024 |
Recent future growth updates
Recent updates
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11
Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Vectoring Back In On Verrica Pharmaceuticals
Aug 31Verrica Pharmaceuticals reports insider buying
Jul 06Verrica Pharmaceuticals stock slides on proposed share offering
Jun 29Verrica Pharmaceuticals Should Receive Second CRL Today
May 24Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)
Mar 07Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 06Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook
Dec 17FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA
May 28Verrica Pharmaceuticals EPS beats by $0.32
May 07Verrica Pharma refiles US application for lead candidate in infectious skin disease
Dec 23Verrica Pharma receives final FDA minutes regarding NDA resubmission for VP-102 in molluscum
Nov 17Verrica Pharma' VP-102 successful in mid-stage study for genital warts
Nov 10Verrica Pharmaceuticals EPS misses by $0.02
Nov 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 137 | 6 | 68 | 60 | 6 |
| 12/31/2025 | 72 | -39 | -26 | -20 | 6 |
| 12/31/2024 | 24 | -76 | -66 | -61 | 6 |
| 12/31/2023 | 5 | -67 | -39 | -39 | N/A |
| 9/30/2023 | 3 | -48 | -29 | -29 | N/A |
| 6/30/2023 | 9 | -23 | -13 | -12 | N/A |
| 3/31/2023 | 9 | -23 | -15 | -15 | N/A |
| 12/31/2022 | 9 | -24 | -19 | -19 | N/A |
| 9/30/2022 | 9 | -28 | -23 | -22 | N/A |
| 6/30/2022 | 1 | -41 | -35 | -35 | N/A |
| 3/31/2022 | 0 | -43 | -26 | -25 | N/A |
| 12/31/2021 | 12 | -35 | -28 | -28 | N/A |
| 9/30/2021 | 12 | -39 | -26 | -25 | N/A |
| 6/30/2021 | 12 | -36 | -23 | -22 | N/A |
| 3/31/2021 | 12 | -34 | -34 | -33 | N/A |
| 12/31/2020 | N/A | -43 | -32 | -30 | N/A |
| 9/30/2020 | N/A | -37 | -33 | -32 | N/A |
| 6/30/2020 | N/A | -33 | -33 | -32 | N/A |
| 3/31/2020 | N/A | -31 | -30 | -28 | N/A |
| 12/31/2019 | N/A | -28 | -28 | -27 | N/A |
| 9/30/2019 | N/A | -28 | -27 | -26 | N/A |
| 6/30/2019 | N/A | -28 | -25 | -24 | N/A |
| 3/31/2019 | N/A | -26 | -23 | -23 | N/A |
| 12/31/2018 | N/A | -21 | -19 | -18 | N/A |
| 9/30/2018 | N/A | -20 | -13 | -13 | N/A |
| 6/30/2018 | N/A | -15 | -9 | -9 | N/A |
| 3/31/2018 | N/A | -11 | -6 | -6 | N/A |
| 12/31/2017 | N/A | -10 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VRCA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: VRCA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VRCA is expected to become profitable in the next 3 years.
Revenue vs Market: VRCA's revenue (47.8% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: VRCA's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VRCA's Return on Equity is forecast to be high in 3 years time